Silver Book Fact

Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye Disease Study (AREDS) nutritional formula could help 300,000 of those 1.3 million avoid the severe vision loss of advanced AMD over a 5-year period.

Bressler N, Bressler S, Congdon N, Ferris F, et al. Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11. Arch Opthalmol. 2003; 121(11): 1621-4. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/415852

Reference

Title
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11
Publication
Arch Opthalmol
Publication Date
2003
Authors
Bressler N, Bressler S, Congdon N, Ferris F, et al.
Volume & Issue
Volume 121, Issue 11
Pages
1621-4
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.  
  • Family risk of glaucoma
    “‘Five of my nine brothers and sisters had glaucoma,’ says 81-year-old Jean R. who for 20 years has depended on eye drops to decrease pressure inside her eyes. Jean is…  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.